Turner S T, Schwartz G L, Chapman A B, Hall W D, Boerwinkle E
Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA.
J Hypertens. 2001 Jan;19(1):1-11. doi: 10.1097/00004872-200101000-00001.
Pharmacogenetic investigation seeks to identify genetic factors that contribute to interpatient and interdrug variation in responses to antihypertensive drug therapy. Classical studies have characterized single gene polymorphisms of drug metabolizing enzymes that are responsible for large interindividual differences in pharmacokinetic responses to several antihypertensive drugs. Progress is being made using candidate gene and genome scanning approaches to identify and characterize many additional genes influencing pharmacodynamic mechanisms that contribute to interindividual differences in responses to antihypertensive drug therapy. Knowledge of polymorphic variation in these genes will help to predict individual patients' blood pressure responses to antihypertensive drug therapy and may also provide new insights into molecular mechanisms responsible for elevation of blood pressure.
药物遗传学研究旨在确定导致患者间和药物间抗高血压药物治疗反应差异的遗传因素。经典研究已对药物代谢酶的单基因多态性进行了特征描述，这些多态性导致了几种抗高血压药物的药代动力学反应存在较大个体差异。目前正在使用候选基因和基因组扫描方法取得进展，以识别和表征许多其他影响药效学机制的基因，这些机制导致了抗高血压药物治疗反应的个体差异。了解这些基因的多态性变异将有助于预测个体患者对抗高血压药物治疗的血压反应，还可能为血压升高的分子机制提供新的见解。
